William Blair Weighs in on QIAGEN's Q1 Earnings (NYSE:QGEN)

Key Points

• William Blair has raised its Q1 2026 earnings per share estimate for Qiagen to $0.57, reflecting a positive outlook compared to the prior estimate of $0.55.
• Qiagen's recent earnings report showed $0.60 per share, meeting analyst expectations, and reported revenues of $533.54 million, above the estimated $523.97 million.
• The company announced a $0.25 dividend per share, representing a yield of 52.0%, with a low payout ratio of 14.79%.

QIAGEN N.V. (NYSE:QGEN - Free Report) - Research analysts at William Blair raised their Q1 2026 earnings estimates for shares of QIAGEN in a note issued to investors on Thursday, August 7th. William Blair analyst A. Brackmann now anticipates that the company will earn $0.57 per share for the quarter, up from their prior estimate of $0.55. The consensus estimate for QIAGEN's current full-year earnings is $2.26 per share.

A number of other research firms have also issued reports on QGEN. Cowen restated a "hold" rating on shares of QIAGEN in a report on Thursday. Wall Street Zen upgraded shares of QIAGEN from a "buy" rating to a "strong-buy" rating in a report on Sunday, August 3rd. Barclays began coverage on shares of QIAGEN in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price objective on the stock. Bank of America upped their price objective on shares of QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. Finally, Robert W. Baird upped their price objective on shares of QIAGEN from $42.00 to $43.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Eight equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $49.69.

QIAGEN Trading Down 0.7%

Shares of QGEN stock traded down $0.34 during trading hours on Friday, reaching $48.02. 1,293,968 shares of the stock traded hands, compared to its average volume of 1,636,041. QIAGEN has a 1-year low of $37.63 and a 1-year high of $51.88. The business has a fifty day moving average price of $48.02 and a 200 day moving average price of $43.54. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $10.67 billion, a PE ratio of 28.37, a PEG ratio of 2.45 and a beta of 0.64.

QIAGEN (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.60. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The business had revenue of $533.54 million for the quarter, compared to analyst estimates of $523.97 million. During the same quarter in the previous year, the business earned $0.55 earnings per share. The firm's revenue was up 7.7% compared to the same quarter last year.

QIAGEN Dividend Announcement

The firm also recently declared a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were paid a dividend of $0.25 per share. The ex-dividend date was Wednesday, July 2nd. This represents a dividend yield of 52.0%. QIAGEN's dividend payout ratio is 14.79%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of QGEN. SVB Wealth LLC acquired a new position in QIAGEN in the 1st quarter valued at $31,000. Farther Finance Advisors LLC grew its stake in QIAGEN by 400.5% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company's stock valued at $51,000 after buying an additional 849 shares during the last quarter. Allworth Financial LP grew its stake in QIAGEN by 260.1% in the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company's stock valued at $53,000 after buying an additional 796 shares during the last quarter. Cullen Frost Bankers Inc. grew its stake in QIAGEN by 13,144.4% in the 2nd quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company's stock valued at $57,000 after buying an additional 1,183 shares during the last quarter. Finally, Hilltop National Bank acquired a new position in QIAGEN in the 2nd quarter valued at $66,000. Institutional investors and hedge funds own 70.00% of the company's stock.

QIAGEN Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.